Imricor Medical Systems (ASX:IMR) said it expects a "steady string" of US Food and Drug 510(k) product submissions and approvals through the remainder of the year, according to a Monday filing with the Australian bourse.
During the June quarter, the company's cash balance fell to $50.3 million from $53.9 million in the March quarter.
Shares of the company fell past 3% in recent Monday trade.